


**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger

Judith U. Kim
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beason
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest

Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Laura A. Vogel
Bryan S. Wade
Aaron L. Schwartz
Shannon A. Carroll*

Wesley W. Jones*
Matthew E. Kelley*
Michelle K. Holoubek*
Marsha A. Rose*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey Mills
Danielle L. Letting

Of Counsel
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

December 19, 2005

WRITER'S DIRECT NUMBER:
(202) 772-8625
INTERNET ADDRESS:
ESTEPPE@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1644
Examiner: Ronald B. Schwadron
Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 09/458,302; Filed: December 10, 1999
For: **Inducing Cellular Immune Responses to Carcinoembryonic
Antigen Using Peptide and Nucleic Acid Compositions**
Inventors: **FIKES et al.**
Our Ref: 2060.0080005/EKS/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.111; and
2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mit M Reg No. 54,325

Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

EKS/PAC:dbj
Enclosures

474740_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re-application of:

FIKES *et al.*

Appl. No.: 09/458,302

Filed: December 10, 1999

For: **Inducing Cellular Immune
Responses to Carcinoembryonic
Antigen Using Peptide and Nucleic
Acid Compositions**

Confirmation No.: 8701

Art Unit: 1644

Examiner: Ronald B. Schwadron

Atty. Docket: 2060.0080005/EKS/PAC

Amendment and Reply Under 37 C.F.R. § 1.111

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated March 1, 2005 and the Notice of Non-Compliant Amendment dated November 17, 2005, Applicants submit the following Amendment and Remarks.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the Listing of Claims which begins on page 6 of this paper.

Remarks begin on page 9 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net

addition of claims) are hereby authorized to be charged to our Deposit Account No.

19-0036.